Sanofi has completed its acquisition of Vigil Neuroscience for approximately €405 million, adding the biotech’s experimental Alzheimer’s treatment to the French pharmaceutical giant’s neurology pipeline. The deal represents Sanofi’s latest move to strengthen its presence in neurodegenerative diseases through targeted immunotherapy approaches.
Under the acquisition terms, Sanofi paid €6.91 per share in cash for all outstanding common shares of the Boston-based biotech. Vigil shareholders also received contingent value rights worth €1.73 per share, payable upon the first commercial sale of VG-3927, the company’s lead Alzheimer’s candidate.
The transaction builds on Sanofi’s €34.5 million strategic investment in Vigil from June 2024, which included exclusive negotiation rights for the company’s treatments. That earlier deal provided Sanofi with an inside track to evaluate Vigil’s TREM2-targeting therapeutics before committing to the full acquisition.
Targeting Brain Immune Dysfunction
Vigil’s approach centers on restoring the function of microglia, immune cells that act as the brain’s surveillance system. In Alzheimer’s disease, these cells become dysregulated, leading to debris accumulation and chronic inflammation that contributes to neurodegeneration.
VG-3927, a small molecule targeting the TREM2 receptor, aims to reactivate microglia’s ability to clear harmful proteins and migrate to injury sites. The drug represents a departure from traditional Alzheimer’s treatments, which have shown limited success in stopping or reversing disease progression.
“TREM2 represents a compelling target at the intersection of immune dysregulation and neurodegeneration, particularly in people living with Alzheimer’s because they face devastating cognitive decline with limited treatment options” ~ Houman Ashrafian, head of research and development at Sanofi.
Selective Asset Acquisition
Notably, Sanofi did not acquire VGL101, Vigil’s other clinical program targeting a rare neurodegenerative disease called adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. This selective approach suggests Sanofi’s primary interest lies in VG-3927’s broader market potential for Alzheimer’s disease.
Founded in 2020, Vigil had positioned itself as a specialist in microglial biology, developing treatments for both rare and common neurodegenerative diseases. The company’s work focused on genetically defined subpopulations of Alzheimer’s patients, potentially enabling more targeted therapeutic approaches.
Clinical Development Plans
Sanofi plans to advance VG-3927 into a Phase 2 clinical study in Alzheimer’s patients, leveraging its larger infrastructure and global reach to accelerate development. The acquisition also brings Vigil’s preclinical pipeline, which could support research into other neurodegenerative conditions.
“We look forward to joining forces with Sanofi’s team to leverage Sanofi’s resources, broad platform and far-reaching network to fully unlock and accelerate the development of VG-3927” ~ Ivana Magovčević-Liebisch, Vigil’s president and chief executive officer.
The deal reflects Sanofi’s broader strategy to apply its immunology expertise to neurological disorders, an area where current treatments remain inadequate. Approved Alzheimer’s therapies face stringent eligibility requirements and do not halt disease progression, creating substantial unmet medical need.
Sanofi indicated the acquisition will not impact its 2025 financial guidance, suggesting the integration costs and near-term development expenses are manageable within existing projections. The transaction strengthens the company’s early-stage neurology pipeline at a time when several major pharmaceutical companies are pursuing novel approaches to neurodegenerative diseases.